1. HBW Insight
  2. >>Ingredients & Safety

Not Just J&J’s Problem: The Evolving Talc Litigation Landscape

 
• By Ryan Nelson

Legal experts see cosmetic talc suits flaring along two tracks – either alleging the carcinogenicity of talc itself or linking cancer cases to asbestos-tainted talc sources. At least one attorney sees the latter as a potentially bigger threat to the cosmetics industry with the traditional pool of asbestos defendants drying up.

Cosmetics firms with a history of talc use could find themselves haunted by alleged wrongdoing in their past or simply be victims of circumstance as the plaintiffs’ bar changes direction in ongoing asbestos litigation, attorney Stephen Hoke suggests.

“As if cosmetic talc defendants did not have enough to contemplate with ovarian cancer claims, they are also subject to another emerging class of claims that seek to hold them...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on HBW Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Ingredients & Safety

Allergy Ingredient Itch Warning, ACNU Final Rule Scratch Extent Of FDA Authority For Label Changes

 
• By Malcolm Spicer

Effective date for ACNU OTC switch final rule and finding of severe itching from long-term use of common allergy ingredients are bookends for limits of FDA’s authority for product label changes.

‘We Must Have The Truth’ – Calls For UWWTD Review Intensify As Evidence Looks ‘Shaky’

 
• By David Ridley

The evidence underpinning the “polluter pays” principle of the revised Urban Wastewater Treatment Directive - which calls on Europe's pharmaceutical industry to cough up at least 80% of the cost of updating wastewater treatment facilities - is looking increasingly shaky, according to a new report.

Supplementation Unlikely To Help With Hereditary Hair Loss, Says German Agency

 
• By David Ridley

Germany’s Federal Institute for Risk Assessment says that there is "no evidence that people with androgenetic alopecia have special dietary needs or a special nutrient requirement.”

Melatonin And Buccal Acyclovir On German Switch Committee Agenda

 
• By David Ridley

An application for melatonin as an OTC medicine is on the agenda for the next German switch committee meeting, despite the hormone being widely available in food supplements. Acyclovir as a buccal tablet and second-generation antihistamine rupatadine are also up for discussion.

More from HBW Insight

People On The Move: Appointments at Hermes, Assosalute, Moberg

 
• By Tom Gallen

A round up of the latest European consumer health exec moves: Hermes hires management board chair; Assosalute elects directors; Moberg appoints ex-Orkla Health CEO.

EU Sunscreen Stakeholder Group Pushing For Legally Binding Text For Sun Protection

 
• By Eileen Francis

Personal care, EU government reps discussing a planned revision of the 2006 European Union Suncare Recommendation are pushing for a legally binding text, rather than the recommendation, and considering broadening the definition for sunscreen.

Loper Bright ‘Might Not Be Cataclysmic’ With FDA’s ‘Good Reputation’ For Science – Attorney

 
• By Malcolm Spicer

Bridget Dooling, law school professor who reviewed draft regulations from FDA and other agencies as OMB attorney, says history of federal court decisions in litigation challenging FDA’s interpretation of statutes points to judges typically defer to agency decisions based in science.